Abstract: FR-PO781
Podocyte EGR1 Expression in Patients with Primary Focal Segmental Glomerulosclerosis and Minimal Change Disease
Session Information
- Glomerular Diseases: Mechanisms and Podocyte Biology
October 25, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1401 Glomerular Diseases: Mechanisms, including Podocyte Biology
Authors
- Okabe, Masahiro, Jikei University School of Medicine, Tokyo, Japan
- Koike, Kentaro, Jikei University School of Medicine, Tokyo, Japan
- Tsuboi, Nobuo, Jikei University School of Medicine, Tokyo, Japan
- Matsusaka, Taiji, Tokai University School of Medicine, Ieshara, Japan
- Yokoo, Takashi, Jikei University School of Medicine, Tokyo, Japan
Background
We have reported that early growth response 1 (EGR1) expresses in injured podocytes from early stage in an inducible podocyte-injury mouse model, NEP25. We also found that the percentage of EGR1-positive podocytes (%EGR1pod) is associated with podocyte injury in patients with glomerular diseases. Primary focal segmental glomerulosclerosis (pFSGS) and minimal change disease (MCD) both present nephrotic syndrome but have very different prognoses, suggesting a potential difference in the degree of podocyte injury between these two conditions. In this study, we aim to examine the difference in podocyte EGR1 expression between patients with pFSGS and MCD.
Methods
Adult patients with biopsy-proven pFSGS or MCD who presented acute-onset nephrotic syndrome were enrolled from Jikei University Hospital, Japan, and Jikei University Daisan Hospital, Japan, between 2001 and 2020. Patients over 70 years of age and patients with serum creatinine levels greater than 1.5 mg/dL were excluded. The %EGR1pod was determined through immunohistochemistry and was compared between the pFSGS and MCD groups.
Results
Patients with pFSGS (n = 9) were significantly older than those with MCD (n = 63) (median, 51 [Interquartile range (IQR), 50–58] vs 39 [29–48] years, P = 0.003), but there was no significant difference in sex, urinary protein level, serum albumin level, or serum creatinine level. The %EGR1pod was significantly higher in the pFSGS group than the MCD group (3.02 [2.60–4.97]% vs 0.68 [0.38–1.53]%, P < 0.001) (Figure 1A). Receiver operating curve (ROC) analysis revealed an area under the curve (AUC) of 0.945 [95% confidence interval, 0.876–1] for distinguishing between pFSGS and MCD patients (Figure 1B).
Conclusion
Stronger podocyte injury was observed in patients with pFSGS than in those with MCD, which may impact kidney prognosis. The %EGR1pod may be a useful marker for differentiating pFSGS from MCD.
Funding
- Government Support – Non-U.S.